Immuneering (IMRX) Gross Profit: 2020-2022
Historic Gross Profit for Immuneering (IMRX) over the last 3 years, with Dec 2022 value amounting to $455.
- Immuneering's Gross Profit rose 102.74% to $455 in Q4 2022 from the same period last year, while for Dec 2022 it was $158,830, marking a year-over-year decrease of 82.86%. This contributed to the annual value of $158,830 for FY2022, which is 82.86% down from last year.
- Per Immuneering's latest filing, its Gross Profit stood at $455 for Q4 2022, which was down 97.61% from $19,037 recorded in Q3 2022.
- Immuneering's 5-year Gross Profit high stood at $367,568 for Q3 2020, and its period low was -$16,630 during Q4 2021.
- Over the past 3 years, Immuneering's median Gross Profit value was $191,847 (recorded in 2020), while the average stood at $170,287.
- As far as peak fluctuations go, Immuneering's Gross Profit tumbled by 108.67% in 2021, and later surged by 102.74% in 2022.
- Immuneering's Gross Profit (Quarterly) stood at $191,847 in 2020, then slumped by 108.67% to -$16,630 in 2021, then spiked by 102.74% to $455 in 2022.
- Its Gross Profit stands at $455 for Q4 2022, versus $19,037 for Q3 2022 and $46,486 for Q2 2022.